Bridgebio Oncology Therapeutics, Stock Alpha and Beta Analysis
| BBOT Stock | 12.52 0.15 1.21% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as BridgeBio Oncology Therapeutics,. It also helps investors analyze the systematic and unsystematic risks associated with investing in BridgeBio Oncology over a specified time horizon. Remember, high BridgeBio Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to BridgeBio Oncology's market risk premium analysis include:
Beta 0.75 | Alpha 0.16 | Risk 3.98 | Sharpe Ratio 0.024 | Expected Return 0.0957 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
BridgeBio | Build AI portfolio with BridgeBio Stock |
BridgeBio Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. BridgeBio Oncology market risk premium is the additional return an investor will receive from holding BridgeBio Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in BridgeBio Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate BridgeBio Oncology's performance over market.| α | 0.16 | β | 0.75 |
BridgeBio Oncology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of BridgeBio Oncology's Buy-and-hold return. Our buy-and-hold chart shows how BridgeBio Oncology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.BridgeBio Oncology Market Price Analysis
Market price analysis indicators help investors to evaluate how BridgeBio Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BridgeBio Oncology shares will generate the highest return on investment. By understating and applying BridgeBio Oncology stock market price indicators, traders can identify BridgeBio Oncology position entry and exit signals to maximize returns.
BridgeBio Oncology Return and Market Media
The median price of BridgeBio Oncology for the period between Fri, Oct 3, 2025 and Thu, Jan 1, 2026 is 12.2 with a coefficient of variation of 5.5. The daily time series for the period is distributed with a sample standard deviation of 0.67, arithmetic mean of 12.1, and mean deviation of 0.51. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Bridgebio Pharma Llc of 784720 shares of BridgeBio Oncology subject to Rule 16b-3 | 10/10/2025 |
2 | BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium | 10/30/2025 |
3 | BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress | 11/12/2025 |
4 | Decoding BridgeBio Oncology Therapeutics Inc A Strategic SWOT Insight - GuruFocus | 11/14/2025 |
5 | Wedbush Reiterates BridgeBio Oncology Therapeutics Outperform Recommendation - Nasdaq | 11/25/2025 |
6 | BridgeBio Oncology stock reaches all-time high at 14.87 USD - Investing.com | 12/08/2025 |
7 | BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RASPI3K Breaker, at the San Antonio Breast Cancer Symposium | 12/10/2025 |
8 | BridgeBio Oncology Therapeutics Promising KRAS Drug Developer - In My View, At Least - Seeking Alpha | 12/12/2025 |
About BridgeBio Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including BridgeBio or other stocks. Alpha measures the amount that position in BridgeBio Oncology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
BridgeBio Oncology Investors Sentiment
The influence of BridgeBio Oncology's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BridgeBio. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BridgeBio Oncology's public news can be used to forecast risks associated with an investment in BridgeBio. The trend in average sentiment can be used to explain how an investor holding BridgeBio can time the market purely based on public headlines and social activities around BridgeBio Oncology Therapeutics,. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BridgeBio Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BridgeBio Oncology's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BridgeBio Oncology's news discussions. The higher the estimated score, the more favorable is the investor's outlook on BridgeBio Oncology.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BridgeBio Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BridgeBio Oncology's short interest history, or implied volatility extrapolated from BridgeBio Oncology options trading.
Build Portfolio with BridgeBio Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for BridgeBio Stock Analysis
When running BridgeBio Oncology's price analysis, check to measure BridgeBio Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Oncology is operating at the current time. Most of BridgeBio Oncology's value examination focuses on studying past and present price action to predict the probability of BridgeBio Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Oncology's price. Additionally, you may evaluate how the addition of BridgeBio Oncology to your portfolios can decrease your overall portfolio volatility.